在前列腺动脉栓塞过程中对阴茎附带的保护线圈栓塞对性功能的影响
Andrew Richardson1, Ansh Bhatia2, Aneesha Maini3
1Department of Interventional Radiology, University of Miami, Miller School of Medicine, 1600 NW Ave #1140, Miami, FL, 33136, USA.
Cardiovascular and interventional radiology
|February 6, 2025
概括
在前列腺动脉栓塞 (PAE) 过程中,阴茎附带的线圈栓塞不会对勃起功能或射精功能产生负面影响. 这种对良性前列腺增生症 (BPH) 的辅助技术显示了与传统PAE相似的性健康结果.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 干预性放射学 干预性放射学
- 性健康 性的健康
背景情况:
- 良性前列腺增生 (BPH) 是一种常见的疾病,导致下泌尿道症状 (LUTS).
- 前列腺动脉栓塞 (PAE) 是BPH的有效的微创治疗方法.
- 阴茎附带的线圈栓塞 (cPAE) 是PAE的辅助技术,旨在防止非目标栓塞.
研究的目的:
- 评估和比较接受cPAE和传统PAE (tPAE) 的患者的勃起和射精功能.
- 评估cPAE对因BPH而治疗LUTS的患者的性健康结果的影响.
主要方法:
- 对878名接受了PAE的患者进行了回顾性分析,以检查BPH的二次性LUTS.
- 患者被分为两组:传统的PAE (tPAE,n=828) 和阴茎附带器的线圈栓塞 (cPAE,n=50).
- 性功能使用男性性健康清单 (SHIM) 和射精功能问卷 (EJQ) 在程序前和随访 (3,6,12,24个月) 评估.
主要成果:
- 在手术后3,6,12和24个月,cPAE和tPAE组之间没有观察到与基线相比SHIM得分变化的显著差异.
- 同样,在手术后的3,6个月和12个月,cPAE和tPAE组之间没有发现与基线相比EJQ得分变化的显著差异.
- 在某些后续点,tPAE和cPAE都显示出SHIM得分的统计学上显著改善.
结论:
- 在PAE期间阴茎附带器的辅助线圈栓塞不会对勃起功能或射精功能产生不利影响.
- cPAE是PAE的安全补充剂,在BPH治疗中提供与tPAE相似的性健康结果.
- 这一发现支持使用cPAE优化PAE程序,而不损害患者的性功能.
相关概念视频
01:17Male Sexual Response: Erection & Ejaculation
1.5K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
1.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461